Inlyta®

Inlyta®是一種二線口服標靶藥物, 專門關注內皮細胞VEGF1,2,3受體的腎細胞增殖問題1。 Inlyta®已分別在2012和2013年獲得美國食品藥品監督管理局2 及香港衛生署的認可3,4。

 

參考資料：​

  1. Inlyta® (axitinib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version (August 2014)
  2. FDA Inlyta Approval Press Release. U.S. Food and Drug Administration. Accessed on 17 Oct 2017. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289423.htm
  3. Drug office, Drug information- Inlyta (axitinib) Tab 1mg, Drug database, Drug office, HKSAR Government, 2013, accessed on 17 Oct 2017. Available at https://www.drugoffice.gov.hk/eps/drug/productDetail/en/consumer/75403
  4. Drug office, Drug information- Inlyta (axitinib) Tab 5mg, Drug database, Drug office, HKSAR Government, 2013, accessed on 17 Oct 2017. Available at https://www.drugoffice.gov.hk/eps/drug/productDetail/en/consumer/75405

[PAC17033C/OCT]

Therapeutic Area Sub Category: 
標靶治療 Targeted Therapy